Compare Nano Dimension Ltd - ADR (NNDM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Sanofi SA — how do they compare? Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 289.7× Nano Dimension Ltd - ADR's market cap, and Sanofi SA pays a 6.01% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nano Dimension Ltd - ADR for 43 Days and Sanofi SA for 94 Days on average.
| NNDM | SNY | |
|---|---|---|
Market Cap | $328.52M | $95.18B |
Volume | 1,160,945 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $2.14 | $52.34 |
52-Week Low | $1.21 | $39.51 |
Typical Hold Time | 43 Days | 94 Days |
Enterprise Value | -$76.33M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nano Dimension (NNDM) trades at $1.56, up 0.65% with a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but remains unprofitable with a -135% net margin. Recent strategic actions include cost-cutting initiatives and board changes, with cash reserves of $758M providing operational runway despite negative cash flows.
The outlook remains challenging with persistent losses and negative cash flow, though valuation ratios appear attractive with P/S of 2.73 and P/B of 0.68. Key risks include execution of turnaround strategy and competitive pressures in the industrial 3D printing sector. Analyst sentiment is cautious given the company's ongoing restructuring efforts.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
